Lp(a) is a useful biomarker for helping to identify patients with well controlled LDL-C who are still at risk of coronary artery disease (CAD), according to data from the Young Heart study of patients <60 years with CAD.
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.